SOURCE: Equity Markets Inc

October 07, 2011 09:00 ET

Expert's Economic Outlook, Global - Equity Research on Par Pharmaceutical Companies, Inc. and Targacept, Inc.

MACAU--(Marketwire - Oct 7, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Par Pharmaceutical Companies, Inc. (NYSE: PRX) and Targacept, Inc. (NASDAQ: TRGT). Full content and research is available at www.EquityMarketsInc.com/research.php?id=PRX+TRGT.

Short-term outlooks within US and global economies continue to adjust downward, as US Treasury yields touched their lowest levels in over 65 years. International Monetary Fund downgraded estimates for US growth by 1.0% this year, down from 2.5%. 'Significant downside risks' to the US economy were confirmed by the Federal Reserve pressured by 'strains in global financial markets.'

As the US dollar trades above an eight-month high against the Euro, it highlights a deepening of the Eurozone sovereign debt crisis -- furthered by continued policy inaction from European governments. We expect continued volatility until economic data stabilizes and we see decisive policy action to deal with the Eurozone debt crisis.

Our members are preparing for a turn in tides. Currently, the Credit Suisse Risk Appetite Indicator is at a 30-year low. For the past three occurrences, this level has acted as a leading indicator of large stock market rallies 18 months following.

Equity Markets has reviewed Par Pharmaceutical Companies, Inc. for its current position within the healthcare industry. Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The full research report on Par Pharmaceutical Companies, Inc. (NYSE: PRX) is available here: www.EquityMarketsInc.com/research.php?id=PRX.

Equity Markets has reviewed Targacept, Inc. for its development within the healthcare industry. Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of neuronal nicotinic receptor (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target NNRs. As of December 31, 2010, it had a number of clinical-stage product candidates and preclinical programs. The full research report on Targacept, Inc. (NASDAQ: TRGT) is available here: www.EquityMarketsInc.com/research.php?id=TRGT.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information